FFF Enterprises: BioSupply Trends Newsletter
Monday, Sep 19, 2016

Meta-Analysis Finds Plasma-Derived Porcine Factor VIII More Effective in Treating Hemophilia A

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

In a study that analyzed data from published literature of preclinical and clinical studies of porcine recombinant factor VIII (Obizur, Baxalta) for treatment of severe hemophilia A patients with inhibitors, researchers found it a potentially important therapeutic option. [ read more ]

CDC Updates Annual Influenza Vaccine Recommendations

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices has issued an update to its recommendations regarding the use of seasonal influenza vaccines for the 2016-17 season. [ read more ]

CMS Publishes New Seasonal Influenza Vaccine Rates

The Centers for Medicare and Medicaid Services has published its influenza vaccine pricing and reimbursement rates and codes for the 2016-17 season. [ read more ]

September 28 Is 10th Annual World Rabies Day

Providers are invited to commemorate the 10th World Rabies Day on September 28 with the Global Alliance for Rabies Control and its collaborators, including the Centers for Disease Control and Prevention, to continue the fight to prevent and eliminate the global scourge of rabies. [ read more ]

Industry News

 
 

From Sandoz

The U.S. Food and Drug Administration (FDA) has approved Erelzi (etanercept-szzs), the first biosimilar etanercept, for all indications included in the reference product’s label, including rheumatoid arthritis, plaque psoriasis, psoriatric arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis. [ read more ]

From CSL Behring

CSL Behring’s application for its low-volume subcutaneous C1-esterase inhibitor human replacement therapy for treating hereditary angioedema (HAE) has been accepted by the U.S. Food and Drug Administration (FDA). Upon FDA approval, CSL830 will be the first and only low-volume, subcutaneous, prophylactic treatment option for HAE patients. [ read more ]

From Shire

The U.S. Food and Drug Administration has approved Shire’s CUVITRU (immune globulin subcutaneous [human] 20% solution) to treat adult and pediatric patients 2 years and older with primary immunodeficiency disease. [ read more ]

IVIG & Albumin Supply Index

 
 

Featured Products of the Month

 
HyperRHO S/D
 

HyperRHO® S/D

HyperRHO S/D is a RhO(D) immune globulin (Human) for intramuscular use indicated for: 1) pregnancy and other obstetric conditions; and 2) transfusion. HyperRHO S/D Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the RhO(D) negative mother within 72 hours after birth of an Rh0(D) positive infant. HyperRHO S/D Mini-Dose is recommended to prevent the isoimmunization of RhO(D) negative women at the time of spontaneous or induced abortion of up to 12 weeks' gestation. For transfusion, HyperRHO S/D is used to prevent isoimmunization in Rh0(D) negative individuals who have been transfused with Rh0(D) positive red blood cells or blood components containing red blood cells. [ read more ]
 
 
HyperRAB S/D
 

HyperRAB® S/D

HyperRAB S/D is a rabies immune globulin (Human) for intramuscular use. The rabies vaccine and HyperRAB S/D should be given to all persons suspected of exposure to rabies with one exception: Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. HyperRAB S/D should be administered as promptly as possible after exposure, but can be administered up to the eighth day after the first dose of vaccine is given. [ read more ]

 

What's New at FFF

CEFEPIME  (WG Critical Care)

Cefepime (intravenous infusion) is indicated for the treatment of several types of bacterial infections of the lungs, skin, abdomen and urinary tract.

For more information about Cefepime, go to biosupply.fffenterprises.com

SOTRADECOL  (Mylan)

Sotradecol injection is indicated for the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.

For more information about Sotradecol, go to biosupply.fffenterprises.com

ENTYVIO  (Takeda)

Entyvio (vedolizumab) is indicated for treatment of adults with 1) moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to or demonstrated dependence on corticosteroids to: induce and maintain clinical response or remission, improve endoscopic appearance of the mucosa or achieve corticosteroid-free remission; and 2) moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to or demonstrated dependence on corticosteroids to: achieve clinical response, clinical remission or corticosteroid-free remission.

For more information about Entyvio, go to biosupply.fffenterprises.com

ARIPIPRAZOLE  (Apotex)

Aripiprazole tablets are an atypical antipsychotic used to treat schizophrenia, bipolar disorder, major depressive disorder and irritability associated with autism.

For more information about Aripiprazole, go to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

VERAPAMIL HCI INJECTION  (Exela Pharma Sciences)

Verapamil hydrochloride injectable (HCI) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that works by relaxing the muscles of the heart and blood vessels. It is indicated for the treatment of supraventricular tachyarrhythmias, including 1) rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardia, including those associated with accessory bypass tracts (Wolf-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes), and 2) temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation, except when the atrial flutter and/or fibrillation are associated with accessory bypass tracts (Wolf-Parkinson-White [WPS] and Lown-Ganong-Levine [LGL] syndromes).

For more information about Verapamil HCI, go to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

OMIDRIA  (Omeros)

Omidria is an alpha 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor that is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement. It is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

For more information about Omidria, go to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective July 1, 2016, through September 30, 2016.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Bivigam J1556 $74.81 $73.61
Carimune NF J1566 $68.07 $66.97
Flebogamma J1572 $75.78 $74.56
Gammagard S/D J1566 $68.07 $66.97
Gammaplex J1557 $73.86 $72.67
Octagam J1568 $79.55 $78.28
Privigen J1459 $76.47 $75.24
SCIG
Hizentra J1559 $98.35 $96.77
HyQvia J1575 $129.98 $127.90
IVIG / SCIG
Gammagard Liquid J1569 $80.00 $78.72
Gammaked J1561 $81.80 $80.49
Gamunex-C J1561 $81.80 $80.49

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2016 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.